Compare iShares MSCI Singapore ETF (EWS) vs Hinge Health Inc. Class A Common Stock (HNGE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Singapore ETF vs Hinge Health Inc. Class A Common Stock — how do they compare? iShares MSCI Singapore ETF trades at $31.22 (market cap $1.23B), while Hinge Health Inc. Class A Common Stock trades at $104.95 (market cap $8.48B). The key difference: Hinge Health Inc. Class A Common Stock is far larger — about 6.9× iShares MSCI Singapore ETF's market cap, and Hinge Health Inc. Class A Common Stock is trading nearer its 52-week high, iShares MSCI Singapore ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Singapore ETF for 47 Days and Hinge Health Inc. Class A Common Stock for 0 Days on average.
| EWS | HNGE | |
|---|---|---|
Market Cap | $1.23B | $8.48B |
Volume | 3,153,173 | 879,799 |
Sector | Broad Market / Factor | Health |
52-Week High | $34.57 | $105.14 |
52-Week Low | $26.71 | $31.17 |
Typical Hold Time | 47 Days | 0 Days |
Enterprise Value | — | $8.10B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWS, the iShares MSCI Singapore ETF, trades at $31.54, down slightly by 0.03% on the day. Technical indicators are mixed, with moving averages signaling a bearish trend while oscillators suggest potential oversold conditions. The ETF recently hit a 52-week high, driven by Singapore's strong economic growth and AI momentum. Institutional interest is positive, with Amundi increasing its stake by 4.8% as of its latest 13F filing.
The outlook for EWS is cautiously optimistic, supported by Singapore's resilient economy and institutional inflows. Key risks include stretched valuations after the multi-year rally and sensitivity to regional economic shifts. Investors should weigh the strong momentum against potential pullbacks in a high-valuation environment.
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI Singapore ETF
EWS tracks the MSCI Singapore 25/50 Index, providing targeted exposure to large and mid-cap companies in Singapore. It is heavily weighted toward the financial, industrial, and real estate sectors, serving as a liquid tool for accessing Singapore's stable, dividend-oriented developed economy.
Read more on EWS →About Hinge Health Inc. Class A Common Stock
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →
